Artificial neural networks and prostate cancer—tools for diagnosis and management

Artificial neural networks (ANNs) are mathematical models that are based on biological neural networks and are composed of interconnected groups of artificial neurons. ANNs are used to map and predict outcomes in complex relationships between given 'inputs' and sought-after 'outputs' and can also be used find patterns in datasets. In medicine, ANN applications have been used in cancer diagnosis, staging and recurrence prediction since the mid-1990s, when an enormous effort was initiated, especially in prostate cancer detection. Modern ANNs can incorporate new biomarkers and imaging data to improve their predictive power and can offer a number of advantages as clinical decision making tools, such as easy handling of distribution-free input parameters. Most importantly, ANNs consider nonlinear relationships among input data that cannot always be recognized by conventional analyses. In the future, complex medical diagnostic and treatment decisions will be increasingly based on ANNs and other multivariate models.

[1]  R. Autorino,et al.  Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[2]  G Bartsch,et al.  The problem of cutoff levels in a screened population , 2001, Cancer.

[3]  M. Meves,et al.  Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and Gleason score to predict positive surgical margins. , 2004, Urology.

[4]  H. Cammann,et al.  Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity , 2008, BMC urology.

[5]  C. Baird,et al.  The pilot study. , 2000, Orthopedic nursing.

[6]  U. Capitanio,et al.  Predictive models before and after radical prostatectomy , 2010, The Prostate.

[7]  M. Stöckle,et al.  Artificial neural network analysis (ANNA) of prostatic transrectal ultrasound , 1999, The Prostate.

[8]  Vassilis Poulakis,et al.  Preoperative neural network using combined magnetic resonance imaging variables, prostate specific antigen, and Gleason score to predict prostate cancer recurrence after radical prostatectomy. , 2004, European urology.

[9]  H. Cammann,et al.  External Validation of an Artificial Neural Network and Two Nomograms for Prostate Cancer Detection , 2012, ISRN urology.

[10]  A W Partin,et al.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. , 1998, JAMA.

[11]  Vassilis Poulakis,et al.  Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy. , 2004, Urology.

[12]  G Reibnegger,et al.  Artificial Neural Networks in Laboratory Medicine and Medical Outcome Prediction , 1999, Clinical chemistry and laboratory medicine.

[13]  S. Varambally,et al.  297 FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST , 2009 .

[14]  W. Pitts,et al.  The statistical organization of nervous activity. , 1948, Biometrics.

[15]  Dietmar Schnorr,et al.  Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. , 2006, Clinical chemistry.

[16]  Shiro Baba,et al.  Artificial neural network analysis for predicting pathological stage of clinically localized prostate cancer in the Japanese population. , 2002, Japanese journal of clinical oncology.

[17]  P. Scardino,et al.  Pathologic basis of the sonographic appearance of the normal and malignant prostate. , 1989, The Urologic clinics of North America.

[18]  M. Roobol,et al.  The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer , 2008, The Prostate.

[19]  Sung Il Hwang,et al.  Role of Transrectal Ultrasonography in the Prediction of Prostate Cancer , 2006, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[20]  A. Jemal,et al.  International variation in prostate cancer incidence and mortality rates. , 2012, European urology.

[21]  Daniel Durkin,et al.  A Critical Analysis Of The Literature In The Carroll College Library In The Field Of Economics With Recommendations , 1964 .

[22]  H. Cammann,et al.  A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases , 2009, The Prostate.

[23]  S. Loening,et al.  The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia , 1997, Cancer.

[24]  F. Montorsi,et al.  Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting. , 2011, European urology.

[25]  H. Lilja,et al.  Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. , 1987, The Journal of clinical investigation.

[26]  Tapabrata Maiti,et al.  Bayesian neural networks for bivariate binary data: an application to prostate cancer study , 2005, Statistics in medicine.

[27]  Cristina Garibaldi,et al.  Use of machine learning methods for prediction of acute toxicity in organs at risk following prostate radiotherapy. , 2011, Medical physics.

[28]  Mesut Remzi,et al.  Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. , 2008, European urology.

[29]  Yu-Chuan Li,et al.  Artificial Neural Network to Predict Skeletal Metastasis in Patients with Prostate Cancer , 2009, Journal of Medical Systems.

[30]  Freddie C Hamdy,et al.  Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. , 2005, European urology.

[31]  Pierre I Karakiewicz,et al.  Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. , 2007, European urology.

[32]  H. Cammann,et al.  Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. , 2009, Urology.

[33]  Guido Schwarzer,et al.  Artificial neural networks for diagnosis and prognosis in prostate cancer. , 2002, Seminars in urologic oncology.

[34]  F. Lee,et al.  Transrectal ultrasound in the diagnosis of prostate cancer: Location, echogenicity, histopathology, and staging , 1986, The Prostate.

[35]  J. Affeldt,et al.  The feasibility study , 2019, The Information System Consultant’s Handbook.

[36]  Mesut Remzi,et al.  Artificial neural networks for decision-making in urologic oncology. , 2003, Reviews in urology.

[37]  A W Partin,et al.  Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. , 2001, Urology.

[38]  Shahrokh F. Shariat,et al.  Inventory of prostate cancer predictive tools , 2008, Current opinion in urology.

[39]  H. Klocker,et al.  Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. , 2003, The Journal of urology.

[40]  鮫島 浩,et al.  Population-based study からみた神経予後不良因子の検討 , 2009 .

[41]  P. Snow,et al.  Introduction to artificial neural networks for physicians: Taking the lid off the black box , 2001, The Prostate.

[42]  E. Capaldi,et al.  The organization of behavior. , 1992, Journal of applied behavior analysis.

[43]  H. Cammann,et al.  Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. , 2013, Clinical chemistry.

[44]  Kazutaka Saito,et al.  Development, validation, and head-to-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. , 2008, European urology.

[45]  Lucila Ohno-Machado,et al.  Logistic regression and artificial neural network classification models: a methodology review , 2002, J. Biomed. Informatics.

[46]  H. Cammann,et al.  Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. , 2013, Clinical chemistry.

[47]  M. Kattan,et al.  The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review. , 2008, European urology.

[48]  K. Jung,et al.  Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. , 2011, European urology.

[49]  E D Crawford,et al.  Use of artificial neural networks in the clinical staging of prostate cancer: implications for prostate brachytherapy. , 2000, Techniques in urology.

[50]  J. Schalken,et al.  IMPROVED PREDICTION OF PROSTATE BIOPSY OUTCOME USING PCA3, TMPRSS2:ERG GENE FUSIONS AND SERUM PSA , 2008 .

[51]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[52]  F ROSENBLATT,et al.  The perceptron: a probabilistic model for information storage and organization in the brain. , 1958, Psychological review.

[53]  Dietmar Schnorr,et al.  An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation , 2002, International journal of cancer.

[54]  Klaus Jung,et al.  A (-5, -7) proPSA based artificial neural network to detect prostate cancer. , 2006, European urology.

[55]  A. Partin,et al.  Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma , 2001, Cancer.

[56]  H. Cammann,et al.  Three new serum markers for prostate cancer detection within a percent free PSA‐based artificial neural network , 2006, The Prostate.

[57]  L. Kiemeney,et al.  DD3PCA3-based Molecular Urine Analysis for the Diagnosis of Prostate Cancer , 2003 .

[58]  H. Cammann,et al.  Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network , 2006, Biological chemistry.

[59]  A W Partin,et al.  A neural network predicts progression for men with gleason score 3+4 versus 4+3 tumors after radical prostatectomy. , 2000, Urology.

[60]  Z. Hall Cancer , 1906, The Hospital.

[61]  John A. W. McCall,et al.  Machine learning for improved pathological staging of prostate cancer: A performance comparison on a range of classifiers , 2012, Artif. Intell. Medicine.

[62]  P Finne,et al.  Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. , 2000, Urology.

[63]  Mesut Remzi,et al.  An artificial neural network to predict the outcome of repeat prostate biopsies. , 2003, Urology.

[64]  R W Veltri,et al.  Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. , 1999, Urology.

[65]  G. Sanz,et al.  The use of neural networks and logistic regression analysis for predicting pathological stage in men undergoing radical prostatectomy: a population based study. , 2001, The Journal of urology.

[66]  Anssi Auvinen,et al.  Algorithms based on prostate‐specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false‐postitive PSA results in prostate cancer screening , 2004, International journal of cancer.

[67]  Y. Yamada,et al.  ACR Appropriateness Criteria® external-beam radiation therapy treatment planning for clinically localized prostate cancer. , 2012, Journal of the American College of Radiology : JACR.

[68]  R. Meijer,et al.  The value of an artificial neural network in the decision-making for prostate biopsies , 2009, World Journal of Urology.

[69]  E. Crawford,et al.  Impact of different variables on the outcome of patients with clinically confined prostate carcinoma: prediction of pathologic stage and biochemical failure using an artificial neural network. , 2001, Cancer.

[70]  H. Cammann,et al.  Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. , 2007, Urology.

[71]  Robert W Veltri,et al.  Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. , 2002, Clinical chemistry.

[72]  J Alfred Witjes,et al.  DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. , 2003, European urology.

[73]  D. Chan,et al.  [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. , 2007, The Journal of urology.

[74]  G. Lockwood,et al.  Predicting prostate biopsy outcome: artificial neural networks and polychotomous regression are equivalent models , 2011, International Urology and Nephrology.

[75]  W. Catalona,et al.  Artificial neural networks in the diagnosis and prognosis of prostate cancer: a pilot study. , 1994, The Journal of urology.

[76]  D. E. Neal,et al.  Neural network analysis of combined conventional and experimental prognostic markers in prostate cancer: a pilot study. , 1998, British Journal of Cancer.

[77]  E J Gamito,et al.  Genetic adaptive neural network to predict biochemical failure after radical prostatectomy: a multi-institutional study. , 2001, Molecular urology.

[78]  S. Varambally,et al.  FEASIBILITY AND CLINICAL UTILITY OF A TMPRSS2:ERG GENE FUSION URINE TEST , 2009 .

[79]  A. Ronco,et al.  Improving ultrasonographic diagnosis of prostate cancer with neural networks. , 1999, Ultrasound in medicine & biology.

[80]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.

[81]  A. Roli Artificial Neural Networks , 2012, Lecture Notes in Computer Science.

[82]  H. Klocker,et al.  Prostate-specific antigen (PSA) isoform p2PSA in combination with total PSA and free PSA improves diagnostic accuracy in prostate cancer detection. , 2010, European urology.

[83]  Pierre I Karakiewicz,et al.  An updated catalog of prostate cancer predictive tools , 2008, Cancer.

[84]  S. Webb,et al.  Use of artificial neural networks to predict biological outcomes for patients receiving radical radiotherapy of the prostate. , 2004, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[85]  Ulf Isacsson,et al.  The effectiveness of artificial neural networks in evaluating treatment plans for patients requiring external beam radiotherapy. , 2004, Oncology reports.

[86]  K. Yoshimura,et al.  The use of artificial neural network analysis to improve the predictive accuracy of prostate biopsy in the Japanese population. , 2004, Japanese journal of clinical oncology.

[87]  Klaus Jung,et al.  Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis. , 2011, Clinical chemistry.

[88]  D. Wells,et al.  A medical expert system approach using artificial neural networks for standardized treatment planning. , 1998, International journal of radiation oncology, biology, physics.

[89]  A Errejon,et al.  Artificial neural network model to predict biochemical failure after radical prostatectomy. , 2001, Molecular urology.

[90]  Klaus Jung,et al.  Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. , 2002, Clinical chemistry.

[91]  K. Johnson An Update. , 1984, Journal of food protection.

[92]  A. Tewari,et al.  Novel staging tool for localized prostate cancer: a pilot study using genetic adaptive neural networks. , 1998, The Journal of urology.

[93]  A. H. Piray,et al.  A comparison of artificial neural networks with other statistical approaches , 2010 .

[94]  Peter Bartel,et al.  Outcome prediction for prostate cancer detection rate with artificial neural network (ANN) in daily routine. , 2012, Urologic oncology.

[95]  W. Ellis,et al.  Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. , 2009, European urology.

[96]  Z. Zhang,et al.  Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. , 2000, Urology.

[97]  H. Cammann,et al.  An artificial neural network for five different assay systems of prostate‐specific antigen in prostate cancer diagnostics , 2008, BJU international.

[98]  Shahrokh F. Shariat,et al.  Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature , 2008, Clinical Cancer Research.

[99]  Mattfeldt,et al.  Prediction of prostatic cancer progression after radical prostatectomy using artificial neural networks: a feasibility study , 1999, BJU international.

[100]  Mesut Remzi,et al.  An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml. or less. , 2003, The Journal of urology.

[101]  H. Cammann,et al.  Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection , 2005, BJU international.

[102]  H. Cammann,et al.  Internal validation of an artificial neural network for prostate biopsy outcome , 2010, International journal of urology : official journal of the Japanese Urological Association.

[103]  A. Cestari,et al.  Development and internal validation of a Prostate Health Index based nomogram for predicting prostate cancer at extended biopsy. , 2012, The Journal of urology.

[104]  E. Crawford,et al.  Combining artificial neural networks and transrectal ultrasound in the diagnosis of prostate cancer. , 2003, Oncology.

[105]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[106]  A. Partin,et al.  Preoperative characteristics of high‐Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy , 2012, BJU international.

[107]  A. Partin,et al.  Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. , 1994, The Journal of urology.

[108]  Robin J Leach,et al.  Predicting prostate cancer risk through incorporation of prostate cancer gene 3. , 2008, The Journal of urology.

[109]  Nallasivam Palanisamy,et al.  Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.

[110]  C. Catalano,et al.  Conventional imaging and multiparametric magnetic resonance (MRI, MRS, DWI, MRP) in the diagnosis of prostate cancer. , 2012, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[111]  T. Mattfeldt,et al.  Prediction of Postoperative Prostatic Cancer Stage on the Basis of Systematic Biopsies using Two Types of Artificial Neural Networks , 2001, European Urology.